Elevated erythropoietin (EPO) signals that the body is producing more of the hormone responsible for driving red blood cell production, and the causes range from something as ordinary as living at high altitude to something as serious as kidney cancer. EPO is made primarily in the kidneys and rises whenever the body senses it isn’t getting enough oxygen, but it can also climb because of genetic mutations, hormonal shifts, certain medications, or tumors that secrete the hormone on their own. The health concerns tied to high EPO depend entirely on what’s behind the increase, though many of the downstream risks converge on the same problem: too many red blood cells thickening the blood.
Where EPO Comes From and Why It Rises
EPO is a hormone produced almost exclusively in the kidneys in adults. The cells responsible are a specific type of fibroblast in the kidney’s cortex, and they ramp up EPO production when they detect low oxygen levels through a molecular sensor called HIF-2α.1PubMed. Hypoxia-inducible factor-2alpha-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization When oxygen drops, HIF-2α accumulates in these cells instead of being broken down, and the result is a surge in EPO. That EPO travels through the bloodstream to the bone marrow, where it tells precursor cells to mature into red blood cells. The system is elegant and usually self-correcting: more red cells carry more oxygen, oxygen levels normalize, and EPO production tapers off.
Elevated EPO, then, almost always means something is disrupting this feedback loop. Either the body genuinely lacks oxygen (and EPO is doing its job), or something is tricking the system into thinking oxygen is low when it isn’t. Understanding which scenario you’re in is what makes the difference between a normal physiological response and a sign of disease.
High Altitude and Lung Disease
The most straightforward reason for elevated EPO is genuine hypoxia, meaning your tissues aren’t receiving adequate oxygen. Ascending to high altitude is the classic example. When lowlanders travel to roughly 4,300 meters (about 14,000 feet), EPO levels can spike dramatically within the first couple of days. One study tracking volunteers at altitude found EPO concentration rose by about 590% within the first 24 hours and peaked at around 1,320% above baseline by 48 hours.2PubMed Central. High-Altitude Hypoxia Decreases Plasma Erythropoietin Soluble Receptor Concentration in Lowlanders That surge doesn’t last, though. Longer-term research on mountaineers showed that EPO was elevated one to two days after arriving at 3,500 meters and stayed high upon further ascent, but after several weeks at high altitude it settled back toward sea-level values even as the body maintained its extra red blood cells.3PubMed. Serum erythropoietin in humans at high altitude and its relation to plasma renin The body had adapted; the new, higher red blood cell count was doing the job, so the signal to make more could quiet down. The exception was extreme altitude: climbers at or above 6,300 meters on Everest still showed significantly elevated EPO even after weeks, suggesting the body couldn’t fully compensate at that extreme.3PubMed. Serum erythropoietin in humans at high altitude and its relation to plasma renin
Chronic lung diseases create a similar oxygen deficit without the mountain scenery. Conditions like chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and cyanotic heart disease all reduce how effectively the lungs deliver oxygen to the bloodstream, and the kidneys respond by cranking up EPO. For some of these patients, the resulting overproduction of red blood cells (secondary polycythemia) becomes a problem in its own right. Phlebotomy, the controlled removal of blood to thin it, has been used in these cases and may actually improve oxygen use without harming oxygen delivery, even though it sounds counterintuitive.4PubMed Central. Successful use of phlebotomy to treat severe secondary polycythemia due to chronic lung disease
Obstructive Sleep Apnea as a Hidden Driver
Sleep apnea deserves its own mention because it’s both common and underdiagnosed, and it can quietly push EPO levels up. In obstructive sleep apnea (OSA), the airway repeatedly collapses during sleep, causing intermittent drops in blood oxygen that the body treats as hypoxic episodes. A meta-analysis found that people with OSA have higher hematocrit values than controls, with the difference reaching statistical significance in patients with severe OSA but not in those with mild or moderate disease.5PubMed Central. Is obstructive sleep apnea associated with erythrocytosis? A systematic review and meta-analysis A separate study looking at patients already diagnosed with secondary polycythemia found that the majority had severe OSA, suggesting the two conditions feed into each other.6PubMed Central. Prevalence of Obstructive Sleep Apnea Among Patients with Secondary Polycythemia: A Retrospective Cross-sectional Study
This is worth knowing because someone with unexplained elevated red blood cell counts or high EPO might not immediately connect it to snoring. If you’ve been told your hemoglobin or hematocrit is unusually high and you haven’t been tested for sleep apnea, it’s a reasonable thing to bring up with your doctor. Treating the apnea with continuous positive airway pressure (CPAP) can address the underlying oxygen desaturation, and evidence suggests it can help normalize the elevated blood counts over time.7PubMed. Prevalence of elevated hemoglobin and hematocrit levels in patients with obstructive sleep apnea and the impact of treatment with continuous positive airway pressure: a meta-analysis
Tumors That Produce EPO on Their Own
Some cancers bypass the normal feedback loop entirely by manufacturing EPO themselves. Renal cell carcinoma is the best-known example. Roughly one to five percent of these kidney tumors are associated with polycythemia, and research using tissue-level analysis has confirmed that the malignant cells themselves are the source of EPO production.8Blood. Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia The tumor cells, which originate from the kidney’s tubular lining, produce EPO constitutively, meaning they do it regardless of whether the body actually needs more red blood cells. EPO and its receptor are expressed in many cancers beyond kidney tumors as well.9PubMed Central. Functional significance of erythropoietin in renal cell carcinoma
Other tumors associated with ectopic EPO production include hepatocellular carcinoma (liver cancer), cerebellar hemangioblastoma (a tumor in the brain’s vascular tissue), uterine fibroids, and pheochromocytoma (an adrenal gland tumor). Finding an unexpectedly high EPO level, especially when accompanied by elevated red blood cell counts and no obvious respiratory explanation, can sometimes be the first clue that a tumor exists. This is one of the reasons doctors don’t dismiss polycythemia as harmless when they can’t explain it.
Genetic Mutations and Chuvash Polycythemia
Some people have permanently elevated EPO because of inherited mutations in the oxygen-sensing machinery. The best-characterized example is Chuvash polycythemia, named after the Chuvash population of Russia where it was first identified. The condition is caused by a specific mutation in the VHL gene. VHL normally helps the body destroy HIF (the oxygen sensor) when oxygen levels are adequate. When VHL is mutated, HIF-1α isn’t broken down efficiently, so the body behaves as though it’s constantly hypoxic, producing excess EPO, along with extra transferrin, glucose transporters, and vascular growth factors.10Nature Genetics. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia
People with Chuvash polycythemia have lifelong elevations in red blood cell mass and face a substantially increased risk of blood clots. Other rare mutations in the oxygen-sensing pathway, including in genes encoding HIF-2α itself or the enzyme prolyl hydroxylase that tags HIF for destruction, can produce similar pictures. These genetic causes are uncommon, but they’re important to identify because they change how the polycythemia is managed over a patient’s lifetime. Unlike altitude-related EPO increases, the stimulus never goes away.
Hormones and Medications That Push EPO Up
Testosterone is a well-known stimulator of EPO production. Testosterone replacement therapy in men can induce erythrocytosis, and one of the mechanisms is a direct increase in EPO secretion along with suppression of hepcidin, a hormone that regulates iron availability.11PubMed Central. Testosterone Induces Erythrocytosis via Increased Erythropoietin and Suppressed Hepcidin: Evidence for a New Erythropoietin/Hemoglobin Set Point This is why men on testosterone replacement are routinely monitored with blood counts, and why dose adjustments or periodic blood donation may be recommended if hematocrit climbs too high.
A newer class of diabetes and heart failure drugs, the SGLT2 inhibitors, has also been observed to stimulate EPO and modestly boost red blood cell production. The exact mechanism is still debated. One hypothesis involves improved kidney oxygenation rejuvenating the EPO-producing fibroblasts, but the available evidence has not clearly confirmed this explanation; for instance, a different drug that improves kidney cortex oxygenation through a similar pathway does not stimulate EPO production at all.12European Heart Journal. Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium–glucose cotransporter 2 inhibitors For patients on SGLT2 inhibitors, the EPO increase is usually modest and the resulting rise in hemoglobin is thought to be part of why these drugs benefit heart failure outcomes, but it’s an area where the science is still catching up to clinical observations.
Why Too Much EPO Becomes Dangerous
The core danger of persistently elevated EPO is what it does downstream: it produces too many red blood cells. As red blood cell count rises, the blood becomes thicker and more viscous. Red blood cells contribute to clot formation by physically interacting with platelets and influencing how tightly clots pack together.13Thieme / PubMed Central. The Role of Red Blood Cells in Hemostasis At normal concentrations, this is a feature of healthy wound healing. At excessively high concentrations, it becomes a liability.
Hypertension is another well-established risk. EPO raises blood pressure through mechanisms that go beyond simply thickening the blood; it has direct effects on blood vessel tone that are independent of its role in making red cells.14PubMed. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA) Hypertension, thrombosis, and stroke are all recognized complications when EPO (or drugs that mimic it) pushes hemoglobin too high.15PubMed Central. Erythropoietin-Induced Hypertension: A Review of Pathogenesis, Treatment, and Role of Blood Viscosity This was brought into sharp relief by clinical trials in kidney disease patients, where aiming for higher hemoglobin targets with EPO-stimulating agents didn’t help and actually raised the risk of heart attack, heart failure, stroke, and death.16PubMed Central. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes
These trials fundamentally changed how EPO-based drugs are prescribed. Modern guidelines for anemia in kidney disease now recommend more conservative hemoglobin targets rather than trying to normalize the count entirely, a recognition that the cardiovascular risks of overshoot are real.
How Doctors Investigate Elevated EPO
When a blood test comes back showing elevated hemoglobin or hematocrit, measuring EPO is typically one of the first steps in figuring out why. The EPO level itself helps sort the possibilities into two broad buckets. A low EPO in the setting of elevated red blood cells points toward a primary bone marrow problem like polycythemia vera, where the marrow is overproducing cells on its own and the body has appropriately suppressed EPO in response. A normal or elevated EPO, on the other hand, points toward a secondary cause, meaning something outside the marrow is driving the overproduction.17PubMed. Erythrocytosis: Diagnosis and investigation
This distinction matters because the management is completely different. Polycythemia vera is a blood cancer treated by hematologists with phlebotomy and sometimes medications like hydroxyurea or JAK inhibitors. Secondary polycythemia, by contrast, is treated by addressing whatever is causing the EPO elevation, whether that’s sleep apnea, a tumor, altitude exposure, or a medication side effect. Early research found that EPO measurements could correctly classify patients as having primary versus secondary polycythemia in over 90% of cases.18PubMed. Erythropoietin radioimmunoassay in evaluating patients with polycythemia Modern workups still lean on EPO as the first branching point, supplemented by genetic testing for the JAK2 mutation found in most polycythemia vera patients.19PubMed Central. Polycythemia Vera With High Serum Erythropoietin Level: A Case Report and Literature Review Measuring serum EPO is simple, inexpensive, and reliable enough to serve as the recommended first-intention test for anyone with unexplained erythrocytosis.20Haematologica. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis
EPO, Tumor Growth, and Angiogenesis
Beyond the blood-thickening risks, elevated EPO raises a separate concern in people with cancer. Research has shown that EPO can accelerate tumor growth by stimulating the formation of new blood vessels within tumors, a process called angiogenesis. In one study using colon cancer models, EPO activated signaling pathways that promoted cancer cell growth and increased the expression of receptors involved in blood vessel formation.21PubMed Central. Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts The researchers concluded that EPO increases the risk of tumor progression in colon cancer and recommended against using it to treat anemia in those patients.
What makes this finding especially concerning is that the tumor-promoting effect doesn’t require the cancer cells themselves to have EPO receptors. Separate research demonstrated that EPO sped up the growth of tumors lacking EPO receptors entirely, because it was acting on the blood vessel cells within the tumor instead. Those endothelial cells expressed the EPO receptor, and EPO stimulated them to proliferate and survive, fueling the tumor’s blood supply from the outside.22Neoplasia. Erythropoietin Promotes the Growth of Tumors Lacking Its Receptor and Decreases Survival of Tumor-Bearing Mice by Enhancing Angiogenesis This has made oncologists particularly cautious about prescribing EPO-based drugs to treat cancer-related anemia, especially when alternatives like transfusions or iron supplementation are available.
EPO Beyond Red Blood Cells
EPO does more than make red blood cells, and this is relevant to understanding why elevated levels produce complex effects throughout the body. EPO receptors appear in non-blood tissues including the brain, heart, and blood vessels. In these tissues, EPO signaling works through a different receptor setup, a pairing of the classic EPO receptor with a second molecule (beta common receptor) that forms what researchers call a tissue-protective receptor.23Cell Death & Disease. Erythropoietin and its derivatives: from tissue protection to immune regulation Through this pathway, EPO participates in wound healing, blood vessel formation, and protective responses in the brain and heart after injury.24PubMed. The non-haematopoietic biological effects of erythropoietin
This dual life creates a tension in clinical medicine. Some of EPO’s non-blood-cell effects look protective, which is why researchers have explored it as a treatment for stroke and heart attack. But those same pathways in the wrong context, such as in the presence of a tumor, can be harmful. The finding that EPO promotes blood vessel growth is a benefit in a healing wound and a danger in a growing cancer. Elevated EPO from any cause means all of these pathways are more active simultaneously, which is part of why the downstream effects are so varied and context-dependent.
Doping and Exogenous EPO Misuse
The same red-blood-cell-boosting property that makes EPO medically useful made it notorious in endurance sports. Injecting synthetic EPO raises hemoglobin and improves oxygen delivery to muscles, which is a direct performance advantage in events like cycling and distance running. The practice became widespread in professional cycling during the 1990s before testing methods caught up. While microdosing strategies have reduced the most acute dangers, long-term misuse of EPO-stimulating agents still carries a risk of serious and sometimes irreversible side effects.25Molecular and Cellular Endocrinology. Erythropoietin as a performance-enhancing drug: Its mechanistic basis, detection, and potential adverse effects
The dangers parallel what happens in clinical overuse: thicker blood raises the risk of clots, stroke, and sudden cardiac events, particularly during sleep or rest when heart rate drops and sluggish, viscous blood is more likely to clot. Anti-doping agencies now test for synthetic EPO variants using blood passport programs that track an athlete’s hematological markers over time, flagging suspicious fluctuations even if a specific drug test comes back negative.
Evolutionary Shortcuts in High-Altitude Populations
Not everyone’s body responds to low oxygen by flooding the bloodstream with EPO. Populations that have lived at high altitude for thousands of years have evolved different strategies. Sherpas, the Himalayan population famous for their high-altitude endurance, show a striking adaptation: their EPO levels at 3,440 meters are essentially the same as those of lowland Nepalese measured at 1,300 meters.26PLOS ONE. Genetic Variants in EPAS1 Contribute to Adaptation to High-Altitude Hypoxia in Sherpas Genetic variants in the EPAS1 gene, which encodes HIF-2α (the same oxygen sensor that triggers EPO production in the kidney), appear to be responsible. Instead of ramping up EPO and packing the blood with extra red cells, Sherpas have adapted to extract and use oxygen more efficiently at the tissue level.
Tibetan populations share similar EPAS1 variants, and Andean highlanders have their own distinct set of adaptations. These natural experiments illustrate that the body’s default response to hypoxia, producing more EPO and more red cells, is not the only possible solution. It is actually a somewhat blunt instrument that evolution has refined away in populations where the cost of chronically thick blood (clotting, stroke, heart failure) outweighed the benefit of a few extra red cells. For the rest of us who lack these adaptations, a sustained EPO elevation at altitude is doing its best, but it comes with trade-offs our bodies aren’t fully optimized to handle.